Literature DB >> 11930312

Suppression of human immunodeficiency virus replication during acute measles.

William J Moss1, Judith J Ryon, Mwaka Monze, Felicity Cutts, Thomas C Quinn, Diane E Griffin.   

Abstract

To determine the effect of measles virus coinfection on plasma human immunodeficiency virus (HIV) RNA levels, a prospective study of hospitalized children with measles was conducted between January 1998 and October 2000 in Lusaka, Zambia. Plasma HIV RNA levels were measured during acute measles and 1 month after hospital discharge. The median plasma HIV RNA level in 33 children with measles who were followed longitudinally was 5339 copies/mL at study entry, 60,121 copies/mL at hospital discharge, and 387,148 copies/mL at 1-month follow-up. The median plasma HIV RNA level in children without acute illness was 228,454 copies/mL. Plasma levels of immune activation markers were elevated during the period of reduced plasma HIV RNA. Plasma levels of several potential HIV suppressive factors also were elevated during acute measles. HIV replication is transiently suppressed during acute measles at a time of intense immune activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11930312     DOI: 10.1086/340027

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Profile of Diane E. Griffin.

Authors:  Nick Zagorski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-08       Impact factor: 11.205

Review 2.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.

Authors:  Kayvon Modjarrad; Eric Chamot; Sten H Vermund
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

3.  In vitro suppression of human immunodeficiency virus type 1 replication by measles virus.

Authors:  Mayra García; Xiao-Fang Yu; Diane E Griffin; William J Moss
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Sterol regulatory element-binding protein 2 couples HIV-1 transcription to cholesterol homeostasis and T cell activation.

Authors:  Harry E Taylor; Michael E Linde; Atanu K Khatua; Waldemar Popik; James E K Hildreth
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

5.  Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27.

Authors:  J Mohamad Fakruddin; Richard A Lempicki; Robert J Gorelick; Jun Yang; Joseph W Adelsberger; Alfonso J Garcia-Pineres; Ligia A Pinto; H Clifford Lane; Tomozumi Imamichi
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

Review 6.  Coinfecting viruses as determinants of HIV disease.

Authors:  Andrea Lisco; Christophe Vanpouille; Leonid Margolis
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

7.  Suppression of human immunodeficiency virus type 1 viral load during acute measles.

Authors:  William J Moss; Susana Scott; Zaza Ndhlovu; Mwaka Monze; Felicity T Cutts; Thomas C Quinn; Diane E Griffin
Journal:  Pediatr Infect Dis J       Date:  2009-01       Impact factor: 2.129

8.  Significantly reduced CCR5-tropic HIV-1 replication in vitro in cells from subjects previously immunized with Vaccinia Virus.

Authors:  Raymond S Weinstein; Michael M Weinstein; Kenneth Alibek; Michael I Bukrinsky; Beda Brichacek
Journal:  BMC Immunol       Date:  2010-05-18       Impact factor: 3.615

9.  Contrasting roles for TLR ligands in HIV-1 pathogenesis.

Authors:  Beda Brichacek; Christophe Vanpouille; Yana Kiselyeva; Angelique Biancotto; Melanie Merbah; Ivan Hirsch; Andrea Lisco; Jean Charles Grivel; Leonid Margolis
Journal:  PLoS One       Date:  2010-09-20       Impact factor: 3.240

10.  Inhibition of HIV-1 infection by monoclonal antibodies to carbohydrates of Schistosoma mansoni.

Authors:  Marco Antônio Gomes Mello; Rita Elizabeth Mascarenhas; Geraldo Argolo Ferraro; Donald Harn; Marco Galvão-Castro; Dumith Chequer Bou-Habib
Journal:  Med Microbiol Immunol       Date:  2005-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.